1. Littrell RA, Hayes LR, Stillner V. Carisoprodol (Soma): a new and cautious perspective on an old agent. South Med J 1993; 86: 753–756.
2. Toth PP, Urtis J. Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clin Ther 2004; 26: 1355–1367.
3. Rho JM, Donevan SD, Rogawski MA. Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther 1997; 280: 1383–1391.
4. Ewing JA, Fullilove RE. Addiction to meprobamate. N Engl J Med 1957; 257: 76–77.
5. Gonzalez LA, Gatch MB, Forster MJ, et al. Abuse potential of Soma: the GABA(A) receptor as a target. Mol Cell Pharmacol 2009; 1: 180–186.
6. Fass JA. Carisoprodol legal status and patterns of abuse. Ann Pharmacother 2010; 44: 1962–1967.
7. Morse RM, Chua L. Carisoprodol dependence: a case report. Am J Drug Alcohol Abuse 1978; 5: 527–530.
8. Luehr JG, Meyerle KA, Larson EW. Mail-order (veterinary) drug dependence. JAMA 1990; 263: 657.
9. Elder NC. Abuse of skeletal muscle relaxants. Am Fam Physician 1991; 44: 1223–1226.
10. Rust GS, Hatch R, Gums JG. Carisoprodol as a drug of abuse. Arch Fam Med 1993; 429–432.
11. Sikdar S, Basu D, Malhotra AK, et al. Carisoprodol abuse: a report from India. Acta Psychiatr Scand 1993; 88: 302–303.
12. Dougherty RJ. Carisoprodol should be a controlled substance. Arch Fam Med 1995; 4: 582.
13. Heacock C, Bauer MS. Tolerance and dependence risk with the use of carisoprodol. Am Fam Physician 2004; 69: 1622–1623.
14. Reeves RR, Mack JE. Possible dangerous interaction of oxycontin and carisoprodol. Am Fam Physician 2003; 67: 941–942.
15. Littrell RA, Sage T, Miller W. Meprobamate dependence secondary to carisoprodol (Soma) use. Am J Drug Alcohol Abuse 1993; 19: 133–134.
16. Reeves RR, Pinkofsky HB, Carter OS. Carisoprodol: a drug of continuing abuse. J Am Osteopath Assoc 1997; 97: 723–724.
17. Reeves RR, Carter OS, Pinkofsky HB. Use of carisoprodol by substance abusers to modify the effects of illicit drugs. South Med J 1999; 92: 441.
18. Reeves RR, Liberto V. Abuse of combinations of carisoprodol and tramadol. South Med J 2001; 94: 512–514.
19. Reeves RR, Henderson RH, Ladner MD. Carisoprodol abuse in Mississippi. J Miss State Med Assoc 2007; 363–365.
20. Reeves RR, Burke RS. Carisoprodol: abuse potential and withdrawal syndrome. Curr Drug Abuse Reviews 2010; 3: 33–38.
21. Reeves RR, Carter OS, Pinkofsky HB, et al. Carisoprodol (soma): abuse potential and physician unawareness. J Addict Dis 1999; 18: 51–56.
22. Owens C, Pugmire B, Salness T, et al. Abuse potential of carisoprodol: a retrospective review of Idaho Medicaid pharmacy and medical claims data. Clin Ther 2007; 29: 2222–2225.
23. Wyller TB, Korsmo G, Gadeholt G. Dependence on carisoprodol (Somadril)? A prospective study among prisoners. Tidsskr Nor Laegeforen 1991; 111: 193–195.
24. Reeves RR, Parker JD. Somatic dysfunction during carisoprodol withdrawal syndrome. J Am Osteopath Assoc 2003; 103: 75–80.
25. Reeves RR, Beddingfield JJ, Mack JE. Carisoprodol withdrawal syndrome. Pharmacotherapy2004; 24: 1804–1806.
26. Rohatgi G, Rissmiller DJ, Gorman JM. Treatment of carisoprodol dependence: a case report. J Psychiatr Pract 2005; 11: 347–352.
27. Reeves RR, Hammer JS, Pendarvis RO. Is the frequency of carisoprodol withdrawal syndrome increasing? Pharmacotherapy 2007; 27: 1462–1466.
28. Eleid MF, Krahn LE, Agrwal N, et al. Carisoprodol withdrawal after internet purchase. Neurologist 2010; 16: 262–264.
29. Roberge RJ, Lin E, Krenzelok EP. Flumazenil reversal of carisoprodol (Soma) intoxication. J Emerg Med 2000; 18: 61–64.
30. Swinyard EA, Chin L, Fingl E. Withdrawal hyperexcitability following chronic administration of meprobamate to mice. Science 1957; 125: 739–741.
31. Gatch MB, Nguyen JD, Carbonaro T, et al. Carisoprodol tolerance and precipitated withdrawal. Drug Alcohol Depend 2012; 123: 29–34.
32. Logan BK, Case GA, Gordon AM. Carisoprodol, meprobamate, and driving impairment. J Forensic Sci 2000; 45: 619–623.
33. Bramness JG, Skurtveit S, Morland J. Impairment due to intake of carisoprodol. Drug Alcohol Depend 2004; 74: 311–318.
34. Hoiseth G, Karinen R, Sorlid HK, et al. The effect of scheduling and withdrawal of carisoprodol on the prevalence of intoxications with the drug. Basic Clin Pharmacol Toxicol 2009; 105: 345–349.
35. Zacny JP, Paice JA, Coalson DW. Characterizing the subjective and psychomotor effects of carisoprodol in healthy volunteers. Pharmacol Biochem Behav 2011; 100: 138–143.
36. Zacny JP, Paice JA, Coalson DW. Subjective and psychomotor effects of carisoprodol in combination with oxycodone in healthy volunteers. Drug Alcohol Depend 2012; 120: 229–232.
38. Substance Abuse and Mental Health Services Administration, Drug Abuse Warning Network.National Estimates of Drug-Related Emergency Department Visits. HHS Publication No. (SMA) 11-4659, DAWN Ser D-35. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2011.
39. Office of Applied Studies, Substance Abuse and Mental Health Services. National survey on drug use and health. www.oas.samhsa.gov/nsduh.htm
. Accessed December 12, 2011.
40. Bronstein AC, Spyker DA, Cantilena LR, et al. 2008 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 26th annual report. Clin Toxicol (Phila) 2009; 47: 911–1084.
41. Deleted in proof.
42. Ukens C. Carisoprodol abuse on rise, warns Mississippi board. Drug Topics 1992; 19: 13.
43. Davis GG, Alexander CB. A review of carisoprodol deaths in Jefferson County, Alabama. South Med J 1998; 91: 726–730.
44. Forrester MB. Carisoprodol abuse in Texas, 1998–2003. J Med Toxicol 2006; 2: 8–13.
45. Deleted in proof.
46. Bramness JG, Furu K, Engeland A, et al. Carisoprodol use and abuse in Norway. A pharmacoepidemiological study. Br J Clin Pharmacol 2007; 64: 210–218.
47. European Medicines Agency. Questions and answers on the recommendation to suspend the marketing authorizations for carisoprodol-containing medicines. Doc. ref. EMEA/520140/2007, November 15, 2007.
48. European Medicines Agency. European Medicines Agency recommends suspension of marketing authorizations for carisoprodol-containing medicinal products. Doc. ref. EMEA/520463/2007, November 16, 2007.
49. Tennessee Board of Pharmacy. Tramadol and carisoprodol now classified schedule IV.Tennessee Board Pharm News 2011; 13: 1.
50. Wyoming Board of Pharmacy. Tramadol and carisoprodol to become Schedule IV in Wyoming. Wyoming State Board Pharm Newsl 2011; 20: 1.
51. Mississippi Board of Pharmacy. Annual controlled substance inventory. Mississippi Board Pharm Newsl May 2011.
52. Drug Enforcement Administration. Schedule of controlled substances: placement of carisoprodol into Schedule IV. Fed Reg 2011; 76: 77330–77360.